What inhaled corticosteroid/long‑acting β‑agonist (ICS/LABA) combination and dosage regimen is recommended for an adult with asthma or mild‑moderate chronic obstructive pulmonary disease (COPD)?

Recommended ICS/LABA Combinations and Dosing

For adults with asthma requiring step 3 or higher therapy, use low-dose ICS/LABA combination therapy as the preferred initial approach, with budesonide/formoterol specifically recommended when considering single maintenance and reliever therapy (SMART). For mild-moderate COPD with frequent exacerbations (≥2 per year), combination ICS/LABA therapy is recommended over LABA monotherapy to reduce exacerbations, though this comes with increased pneumonia risk.

Asthma Management

Specific Combinations and Dosing

Step 3 (Moderate Persistent Asthma):

• Preferred: Low-dose ICS + LABA combination 1
  • Examples: Fluticasone/salmeterol or budesonide/formoterol
  • Alternative: Medium-dose ICS alone

Step 4 (Moderate-Severe Persistent):

• Preferred: Medium-dose ICS + LABA 1

Step 5 (Severe Persistent):

• Preferred: High-dose ICS + LABA 1
• Consider adding omalizumab for allergic asthma

SMART Therapy Considerations

For patients ≥12 years with moderate-severe asthma, ICS/formoterol as both maintenance and reliever therapy (SMART) is strongly recommended over higher-dose ICS alone or same-dose ICS/LABA with SABA rescue 2, 3. Key specifications:

• Formoterol is required - salmeterol has slower onset and should not be used for SMART 2
• Budesonide/formoterol is the evidence-based combination (other ICS theoretically possible but unstudied) 2
• Dosing: Up to 8 puffs/day (ages 5-11) or 10 puffs/day (≥12 years) 2

Mild Persistent Asthma (Step 2)

For adults ≥12 years with mild persistent asthma, two evidence-based options exist 2, 3:

1. Daily low-dose ICS with as-needed SABA (preferred for symptom control)
2. As-needed ICS + SABA used concomitantly (reduces total ICS exposure, noninferior for exacerbations but may have inferior symptom control)

Important caveat: The as-needed strategy requires separate inhalers in the US due to lack of combined ICS/SABA products 2.

COPD Management

ICS/LABA Indications

For moderate-severe COPD, combination ICS/LABA therapy is recommended over LABA monotherapy to prevent acute exacerbations 4, 5. This recommendation (Grade 1C) prioritizes:

• Reduced exacerbation risk
• Improved quality of life and lung function
• Reduced dyspnea and rescue medication use

However, balance this against a 4% increased pneumonia risk 4.

Specific Evidence-Based Combinations

The strongest evidence supports 4:

• Fluticasone/salmeterol (10 studies, most robust data)
• Budesonide/formoterol (4 studies)

Dosing Considerations for COPD

Medium-dose ICS is generally sufficient - the dose-response curve is relatively flat 6. The 2023 Canadian Thoracic Society guidelines note:

• No significant difference in exacerbation reduction between moderate and low-dose ICS
• Moderate dose showed mortality benefit in the ETHOS study
• Higher doses increase adverse effects without proportional benefit

Number needed to treat/harm: 4 patients treated for 1 year to prevent one moderate-severe exacerbation; 33 patients for 1 year to cause one pneumonia 6.

When to Use ICS/LABA in COPD

Use ICS/LABA when patients have 4:

• ≥2 exacerbations per year (GOLD categories C and D)
• Moderate to very severe COPD
• Symptoms uncontrolled on single bronchodilator

Alternative consideration: For stable COPD, long-acting anticholinergic/LABA (LAMA/LABA) or LAMA monotherapy are equally effective for preventing exacerbations 4, 5, and recent real-world evidence suggests LAMA/LABA may be more effective than ICS/LABA in patients with no prior exacerbations and FEV₁ <50% predicted 7.

Critical Safety Warnings

Pneumonia Risk

• Increased with all ICS-containing regimens in COPD (class effect) 4, 6
• Risk highest in severe/very severe disease
• Must balance against exacerbation reduction benefits

Never Use LABA Monotherapy

LABAs must never be used as monotherapy for asthma 8 - always combine with ICS due to historical safety concerns regarding asthma-related deaths.

ICS Monotherapy Not Recommended

ICS monotherapy is not supported in COPD 4, 5 - always use in combination with long-acting bronchodilators.

Practical Implementation

Device Selection

• Single-inhaler combinations improve adherence over multiple inhalers 6
• Once-daily formulations offer greatest convenience
• Ensure proper inhaler technique training

Monitoring and Adjustment

• Assess control at each visit
• Step down therapy if well-controlled for ≥3 months in asthma 1
• In COPD, avoid stepping down from triple therapy in high-risk exacerbators 6